Replies to post #130630 on Biotech Values

[mcbio]

Sure the market cap is tiny, what happens if they don't produce anything of value soon? In comes the reverse split.

If they don't produce anything of value within a year or so, or otherwise land a partner or find an acquirer, the stock will be at zero. That's worst-case scenario that one must consider.

I also did not like how they portrayed the old linjeta/viaject either...they compared to regular insulin instead of fast acting stuff out there and the thing was still weak. Management is shady IMHO.

I don't know that it was that Linjeta was weak but rather how the trials were handled in India (nice segue from the TRGT news today). Anyways, the prior CEO is gone and the new CEO has wisely switched to pushing forward by comparing to the fast-acting insulins.

I have not looked at them hard since the CRL but did see when the ph1 trial failed.

The Phase 1 that failed was for recombinant human insulins, and not for the potentially improved insulin analogs that BIOD appears to be focused on right now. I don't see failure with the recombinant human insulins as meaning that the insulin analog program will fail since they are different programs. That doesn't mean the program will be a success either, of course, but I'm not ready to write it off just yet, as I essentially have the RHI program.